1Gorre ME, Mohammed M, Ellwocd K, et al. Clinical resistance to STI - 571 cancer therapy caused by BCR - ABL gene mutation or amphfication [J]. Science, 2001, 293 (5531): 876-880.
2Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy [J]. Leukemia, 2002, 16 (11): 2190- 2196.
3Thomas J, Wang LH, Richard E, et al. Active transport of imatinib into and out of cells: implications for drug resistance [J]. Blood, 2004, 104 (12): 3739-3745.
4Illmer T, Seboieh M, Platzbeeker U, et al. Pglycoprotein - mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cell to treatment with imatinib mesylate [J], Leukemia, 2004, 18 (3): 401-408.
6Dresser M J, Leabman MK, Giacomini KM. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters [ J ]. J Phann Sci, 2001, 90 (4): 397-421.
7Grundenutnn D, Gorboulev V, Gambaryan S, et al. Drug excretion mediated by a new prototype of polyspecific trartsporter [ J ]. Nature, 1994, 372 (8): 549-552.
8Zhang L, Dresser MJ, Gray AT, et al. Cloning and functional expression of a htunan liver organic cation transporter [ J ]. Mol Pharmacol, 1997, 51: 913-921.
9Koehler MR, Wissinger B, Gorboulev V, et al. The two human organic cation transporter genes SLC22AI and SLC22A2 are lo- cated on chromosome 6q26 [J]. Cytogenet. Cell Genet, 1997, 79 (3- 4): 198- 200.
10Crossman LC, Druker BJ, Deininger WN, et al. hOCF1 and resistance to imatinib [J]. Blood, 2005, 106 (3): 1133- 1134.
二级参考文献10
1Eap CB, Fellay J, Buclin T, et al. CYP3A activity measured by the midazolam test is not related to 3435 C > T polymorphism in the multiple drug resistance transporter gene.Phannaeogeneties, 2004, 14 : 255 -260.
2Hitzl M, Schaeffeler E, Hocher B, et al. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the mulfidrug resistance 1 gene(MDR1, ABCB1). Pharmacogenetics, 2004, 14:309 -318.
3Meissner K, Jedlitschky G, Meyer SH, et al. Modulation of multidrug resistance P-glycoprotein 1 ( ABCB1 ) expression in human heart by hereditary polymorphisms. Pharmacogenetics, 2004, 14 : 381 -385.
4Yi SY, Hong KS, Lim HS, et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmaeol Ther, 2004, 76 : 418 -427.
5Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation, 2004, 78 : 1182- 1187.
6Haufroid V, Mourad M, Van Kerckhove V, et al. The effectof CYP3A5 and MDR1 ( ABCB1 ) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics,2004, 14 : 147- 154.
7Lang T, Hitzl M, Burk O, et al. Genetic polymorphisms in the muhidrug resistance-associated protein 3 (ABCC3,MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics, 2004, 14 : 155-164.
8Wang H, Hao B, Zhou K, et al. Linkage disequilibrium and haplotype architecture for two ABC transporter genes(ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies. Ann Hum Genet,2004, 68 : 563 -573.
9Ieiri I, Suzuki H, Kimura M, et al. Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1 A1,and MRP2) on serum bilirubin levels in healthy subjects.Hepatol Res, 2004, 30 : 91 -95.
10Sakata T, Anzai N, Shin H J, et al. Novel single nucleotide polymorphisms of organic cation transporter 1 ( SLC22A1 )affecting transport functions. Biochem Biophys Res Commun, 2004, 313 : 789 -793.
